



LabCorp Burlington  
 1447 York Court  
 Burlington, NC 27215-3361

Phone: 800-762-4344

Specimen Number <b>286-992-9001-0</b>	Patient ID	Control Number	Account Number 90000999	Account Phone Number 336-436-8645	Route 00
<b>SAMPLE REPORT</b>			Account Address		
Patient Last Name			LabCorp Test Master		
Patient First Name <b>123638</b>		Patient Middle Name	Test Account		
Patient SS#	Patient Phone	Total Volume	3060 South Church Street		
Age (Y/M/D) 56/10/29	Date of Birth 11/13/59	Sex M	Fasting	Burlington NC 27215	
Patient Address			Additional Information		
			NORMAL REPORT		
Date and Time Collected 10/12/16 00:00	Date Entered 10/12/16	Date and Time Reported	Physician Name	NPI	Physician ID

Tests Ordered					
NMR LipoProf wSubCls+Graph					

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
-------	--------	------	-------	--------------------	-----

<b>NMR LipoProf wSubCls+Graph</b>					
LDL Particle Number					01
LDL-P	900		nmol/L	<1000	01
			Low	< 1000	
			Moderate	1000 - 1299	
			Borderline-High	1300 - 1599	
			High	1600 - 2000	
			Very High	> 2000	
Lipids					01
LDL-C	85		mg/dL	0 - 99	
			Optimal	< 100	
			Above optimal	100 - 129	
			Borderline	130 - 159	
			High	160 - 189	
			Very high	> 189	
Comment:					01
LDL-C is inaccurate if patient is non-fasting.					
HDL-C	50		mg/dL	>39	01
Triglycerides	75		mg/dL	0 - 149	01
Cholesterol, Total	150		mg/dL	100 - 199	01
LDL and HDL Particles					01
HDL-P (Total)	35.0		umol/L	>=30.5	01
Small LDL-P	500		nmol/L	<=527	01
LDL Size	21.0		nm	>20.5	01

-----  
 \*\* INTERPRETATIVE INFORMATION\*\*

PARTICLE CONCENTRATION AND SIZE

<--Lower CVD Risk Higher CVD Risk-->

LDL AND HDL PARTICLES Percentile in Reference Population

HDL-P (total)	High	75th	50th	25th	Low
	>34.9	34.9	30.5	26.7	<26.7

Small LDL-P	Low	25th	50th	75th	High
-------------	-----	------	------	------	------

<b>SAMPLE REPORT, 123638</b>		<b>286-992-9001-0</b>	Seq # 0000
------------------------------	--	-----------------------	------------

10/13/16 07:52 ET

**DUPLICATE FINAL REPORT**

Page 1 of 3

This document contains private and confidential health information protected by state and federal law.

©2004-16 Laboratory Corporation of America ® Holdings

If you have received this document in error, please call 800-222-7566

All Rights Reserved

DOC1 Ver: 1.49



LabCorp Burlington  
1447 York Court  
Burlington, NC 27215-3361

Phone: 800-762-4344

<b>SAMPLE REPORT, 123638</b>					Patient Name			Specimen Number <b>286-992-9001-0</b>		
Account Number 90000999	Patient ID	Control Number	Date and Time Collected 10/12/16 00:00	Date Reported	Sex M	Age(Y/M/D) 56/10/29	Date of Birth 11/13/59			

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
	<117	117	527	839	>839
LDL Size	<-Large (Pattern A)->	<-Small (Pattern B)->			
	23.0	20.6	20.5	19.0	

Comment: Small LDL-P and LDL Size are associated with CVD risk, but not after LDL-P is taken into account. 01

These assays were developed and their performance characteristics determined by LipoScience. These assays have not been cleared by the US Food and Drug Administration. The clinical utility of these laboratory values have not been fully established.

Insulin Resistance/Diab. Risk	RESULT	UNITS	REFERENCE INTERVAL	LAB
Large VLDL-P	1.0	nmol/L	<=2.7	01
Small LDL-P	500	nmol/L	<=527	01
Large HDL-P	5.0	umol/L	>=4.8	01
VLDL Size	40.0	nm	<=46.6	01
LDL Size	21.0	nm	>=20.8	01
HDL Size	10.0	nm	>=9.2	01
Insulin Resistance Score				01
LP-IR Score	40		<=45	01

INSULIN RESISTANCE / DIABETES RISK MARKERS  
<--Insulin Sensitive Insulin Resistant-->  
Percentile in Reference Population

Large VLDL-P	Low	25th	50th	75th	High
	<0.9	0.9	2.7	6.9	>6.9
Small LDL-P	Low	25th	50th	75th	High
	<117	117	527	839	>839
Large HDL-P	High	75th	50th	25th	Low
	>7.3	7.3	4.8	3.1	<3.1
VLDL Size	Small	25th	50th	75th	Large
	<42.4	42.4	46.6	52.5	>52.5
LDL Size	Large	75th	50th	25th	Small
	>21.2	21.2	20.8	20.4	<20.4
HDL Size	Large	75th	50th	25th	Small
	>9.6	9.6	9.2	8.9	<8.9
Insulin Resistance Score					
LP-IR SCORE	Low	25th	50th	75th	High
	<27	27	45	63	>63

<b>SAMPLE REPORT, 123638</b>		<b>286-992-9001-0</b>	Seq # 0000
------------------------------	--	-----------------------	------------

10/13/16 07:52 ET

DUPLICATE FINAL REPORT

Page 2 of 3

This document contains private and confidential health information protected by state and federal law.

©2004-16 Laboratory Corporation of America ® Holdings

If you have received this document in error, please call 800-222-7566

All Rights Reserved

DOC1 Ver: 1.49



LabCorp Burlington  
 1447 York Court  
 Burlington, NC 27215-3361

Phone: 800-762-4344

<b>SAMPLE REPORT, 123638</b>					Patient Name			Specimen Number <b>286-992-9001-0</b>		
Account Number 90000999	Patient ID	Control Number	Date and Time Collected 10/12/16 00:00	Date Reported	Sex M	Age(Y/M/D) 56/10/29	Date of Birth 11/13/59			

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
-------	--------	------	-------	--------------------	-----

Comment: LP-IR Score is inaccurate if patient is non-fasting. 01

The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment. Neither the LP-IR score nor the subclasses listed above have been cleared by the US Food and Drug Administration.

NMR PDF Image . 01

01	BN	LabCorp Burlington	Dir: William F Hancock, MD
		1447 York Court, Burlington, NC 27215-3361	
For inquiries, the physician may contact Branch: 800-222-7566 Lab: 800-762-4344			

<b>SAMPLE REPORT, 123638</b>		<b>286-992-9001-0</b>	Seq # 0000
------------------------------	--	-----------------------	------------

Specimen Number 286-992-9001-0		Patient ID 123638		Account Number 90000999	Account Phone (336) 436-8645	Account Fax (336) 436-8645
Patient Last Name SAMPLE REPORT		Patient First Name 123638		Account Address <b>LabCorp Test Master Test Account</b> <b>3060 South Church Street</b> <b>Burlington, NC 27215</b>		
Age 56	Date of Birth 11/13/1959	Sex M	Fasting NOT SPECIFIED			
Control Number		NPI				
Date Collected 10/12/2016	Date Entered 10/12/2016	Date and Time Reported 10/12/2016 11:54 AM ET		Physician ID & Name		Page Number 1 of 2

**NMR LipoProfile® test**

**Reference Range<sup>1</sup>**

	Percentile <sup>1</sup>	20th	50th	80th	95th	
nmol/L	Low	Moderate	Borderline High	High	Very High	
<b>LDL-P</b> (LDL Particle Number)	<b>900</b>	<b>&lt; 1000</b>	<b>1000 - 1299</b>	<b>1300 - 1599</b>	<b>1600 - 2000</b>	<b>&gt; 2000</b>


1. Reference population (5,362 men and women) not on lipid medication enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA). Mora, et al. Atherosclerosis 2007.

**Lipids**

mg/dL	Optimal	Near or Above Optimal	Borderline High	High	Very High	
<b>LDL-C</b> (calculated)	<b>85</b>	<b>&lt; 100</b>	<b>100 - 129</b>	<b>130 - 159</b>	<b>160 - 189</b>	<b>≥ 190</b>
<b>HDL-C</b>	<b>50</b>	<b>Triglycerides</b>	<b>75</b>	<b>Total Cholesterol</b>	<b>150</b>	
Desirable ≥ 40		Desirable < 150		Desirable < 200		

LDL-C is inaccurate if patient is non-fasting.

**Historical Reporting**





Issued or Pending Patents

The NMR LipoProfile® test may be covered by one or more issued or pending patents, including U.S. Patent Nos. 6,518,069; 6,576,471; 6,653,140; and 7,243,030

CLIA Number  
34D0655059

Specimen Number 286-992-9001-0		Patient ID 123638		Account Number 90000999	Account Phone (336) 436-8645	Account Fax (336) 436-8645
Patient Last Name SAMPLE REPORT		Patient First Name 123638		Account Address <b>LabCorp Test Master Test Account</b> 3060 South Church Street Burlington, NC 27215		
Age 56	Date of Birth 11/13/1959	Sex M	Fasting NOT SPECIFIED			
Control Number		NPI				
Date Collected 10/12/2016	Date Entered 10/12/2016	Date and Time Reported 10/12/2016 11:54 AM ET		Physician ID & Name		Page Number 2 of 2

## PARTICLE CONCENTRATION AND SIZE



\*\* The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment. Neither the LP-IR score nor the subclasses listed above have been cleared by the US Food and Drug Administration.

① LipoScience reference population comprises 4,588 men and women without known CVD or diabetes and not on lipid medication.

② Shalauraova I et al., Metab Syndr Relat Disord 2014; 12:422-9.

③ Mackey RH et al., Diab Care 2015; 38:628-36.



LabCorp Burlington  
1447 York Court  
Burlington, NC 27215-3361

Phone: 800-762-4344

Specimen Number <b>286-992-9002-0</b>		Patient ID		Control Number	Account Number 90000999	Account Phone Number 336-436-8645	Route 00
<b>SAMPLE REPORT</b>				Account Address LabCorp Test Master			
Patient First Name <b>123638</b>		Patient Middle Name		Test Account			
Patient SS#		Patient Phone		3060 South Church Street			
Age (Y/M/D) 56/10/29		Date of Birth 11/13/59		Sex M	Fasting		
Patient Address				Additional Information ABNORMAL REPORT			
Date and Time Collected 10/12/16 00:00		Date Entered 10/12/16		Date and Time Reported		Physician Name	Physician ID

Tests Ordered NMR LipoProf wSubCls+Graph							
---	--	--	--	--	--	--	--

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
-------	--------	------	-------	--------------------	-----

<b>NMR LipoProf wSubCls+Graph</b>					
LDL Particle Number					01
<b>LDL-P</b>	<b>1680</b>	<b>High</b>	nmol/L	<1000	01
			Low	< 1000	
			Moderate	1000 - 1299	
			Borderline-High	1300 - 1599	
			High	1600 - 2000	
			Very High	> 2000	
Lipids					01
<b>LDL-C</b>	<b>199</b>	<b>High</b>	mg/dL	0 - 99	
			Optimal	< 100	
			Above optimal	100 - 129	
			Borderline	130 - 159	
			High	160 - 189	
			Very high	> 189	
Comment:					01
LDL-C is inaccurate if patient is non-fasting.					
HDL-C	86		mg/dL	>39	01
Triglycerides	72		mg/dL	0 - 149	01
<b>Cholesterol, Total</b>	<b>299</b>	<b>High</b>	mg/dL	100 - 199	01
LDL and HDL Particles					01
HDL-P (Total)	45.0		umol/L	>=30.5	01
Small LDL-P	285		nmol/L	<=527	01
LDL Size	21.8		nm	>20.5	01

-----  
\*\* INTERPRETATIVE INFORMATION\*\*

PARTICLE CONCENTRATION AND SIZE

<--Lower CVD Risk Higher CVD Risk-->

LDL AND HDL PARTICLES Percentile in Reference Population

HDL-P (total)	High	75th	50th	25th	Low
	>34.9	34.9	30.5	26.7	<26.7

Small LDL-P	Low	25th	50th	75th	High
-------------	-----	------	------	------	------

<b>SAMPLE REPORT, 123638</b>		<b>286-992-9002-0</b>	Seq # 0000
------------------------------	--	-----------------------	------------

10/13/16 07:53 ET

**DUPLICATE FINAL REPORT**

Page 1 of 3

This document contains private and confidential health information protected by state and federal law.

©2004-16 Laboratory Corporation of America ® Holdings

If you have received this document in error, please call 800-222-7566

All Rights Reserved

DOC1 Ver: 1.49



LabCorp Burlington  
 1447 York Court  
 Burlington, NC 27215-3361

Phone: 800-762-4344

<b>SAMPLE REPORT, 123638</b>					Patient Name			Specimen Number <b>286-992-9002-0</b>		
Account Number 90000999	Patient ID	Control Number	Date and Time Collected 10/12/16 00:00	Date Reported	Sex M	Age(Y/M/D) 56/10/29	Date of Birth 11/13/59			

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
	<117	117	527	839	>839
LDL Size	<-Large (Pattern A)->	<-Small (Pattern B)->			
	23.0	20.6	20.5	19.0	

Comment: Small LDL-P and LDL Size are associated with CVD risk, but not after LDL-P is taken into account. 01

These assays were developed and their performance characteristics determined by LipoScience. These assays have not been cleared by the US Food and Drug Administration. The clinical utility of these laboratory values have not been fully established.

TESTS	RESULT	UNITS	REFERENCE INTERVAL	LAB
Insulin Resistance/Diab. Risk				01
Large VLDL-P	0.8	nmol/L	<=2.7	01
Small LDL-P	285	nmol/L	<=527	01
Large HDL-P	10.1	umol/L	>=4.8	01
VLDL Size	36.4	nm	<=46.6	01
LDL Size	21.8	nm	>=20.8	01
HDL Size	9.5	nm	>=9.2	01
Insulin Resistance Score				01
LP-IR Score	<25		<=45	01

INSULIN RESISTANCE / DIABETES RISK MARKERS  
 <--Insulin Sensitive Insulin Resistant-->  
 Percentile in Reference Population

Large VLDL-P	Low	25th	50th	75th	High
	<0.9	0.9	2.7	6.9	>6.9
Small LDL-P	Low	25th	50th	75th	High
	<117	117	527	839	>839
Large HDL-P	High	75th	50th	25th	Low
	>7.3	7.3	4.8	3.1	<3.1
VLDL Size	Small	25th	50th	75th	Large
	<42.4	42.4	46.6	52.5	>52.5
LDL Size	Large	75th	50th	25th	Small
	>21.2	21.2	20.8	20.4	<20.4
HDL Size	Large	75th	50th	25th	Small
	>9.6	9.6	9.2	8.9	<8.9
Insulin Resistance Score					
LP-IR SCORE	Low	25th	50th	75th	High
	<27	27	45	63	>63

<b>SAMPLE REPORT, 123638</b>		<b>286-992-9002-0</b>	Seq # 0000
------------------------------	--	-----------------------	------------



LabCorp Burlington  
 1447 York Court  
 Burlington, NC 27215-3361

Phone: 800-762-4344

<b>SAMPLE REPORT, 123638</b>					Patient Name			Specimen Number <b>286-992-9002-0</b>		
Account Number 90000999	Patient ID	Control Number	Date and Time Collected 10/12/16 00:00	Date Reported	Sex M	Age(Y/M/D) 56/10/29	Date of Birth 11/13/59			

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
-------	--------	------	-------	--------------------	-----

Comment: LP-IR Score is inaccurate if patient is non-fasting. 01

The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment. Neither the LP-IR score nor the subclasses listed above have been cleared by the US Food and Drug Administration.

NMR PDF Image . 01

01	BN	LabCorp Burlington	Dir: William F Hancock, MD
		1447 York Court, Burlington, NC 27215-3361	
For inquiries, the physician may contact <b>Branch: 800-222-7566 Lab: 800-762-4344</b>			

<b>SAMPLE REPORT, 123638</b>		<b>286-992-9002-0</b>	Seq # 0000
------------------------------	--	-----------------------	------------



Specimen Number 286-992-9002-0		Patient ID 123638		Account Number 90000999	Account Phone (336) 436-8645	Account Fax (336) 436-8645
Patient Last Name SAMPLE REPORT		Patient First Name 123638		Account Address <b>LabCorp Test Master Test Account</b> 3060 South Church Street Burlington, NC 27215		
Age 56	Date of Birth 11/13/1959	Sex M	Fasting NOT SPECIFIED			
Control Number		NPI				
Date Collected 10/12/2016	Date Entered 10/12/2016	Date and Time Reported 10/12/2016 11:23 AM ET		Physician ID & Name		Page Number 1 of 2

### NMR LipoProfile® test

### Reference Range<sup>1</sup>

	Percentile <sup>1</sup>	20th	50th	80th	95th	
	Low	Moderate	Borderline High	High	Very High	
<b>LDL-P</b> (LDL Particle Number)	<b>1680</b>	< 1000	1000 - 1299	1300 - 1599	1600 - 2000	> 2000

1. Reference population (5,362 men and women) not on lipid medication enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA). Mora, et al. Atherosclerosis 2007.

### Lipids

	Optimal	Near or Above Optimal	Borderline High	High	Very High	
<b>LDL-C</b> (calculated)	<b>199</b>	< 100	100 - 129	130 - 159	160 - 189	≥ 190


199

	mg/dL	mg/dL	mg/dL
<b>HDL-C</b>	<b>86</b>	<b>Triglycerides</b>	<b>72</b>
	Desirable ≥ 40		Desirable < 150
		<b>Total Cholesterol</b>	<b>299</b>
			Desirable < 200

LDL-C is inaccurate if patient is non-fasting.

### Historical Reporting

#### LDL-P



#### LDL-C



Issued or Pending Patents



The NMR LipoProfile® test may be covered by one or more issued or pending patents, including U.S. Patent Nos. 6,518,069; 6,576,471; 6,653,140; and 7,243,030

CLIA Number

34D0655059

Specimen Number 286-992-9002-0		Patient ID 123638		Account Number 90000999	Account Phone (336) 436-8645	Account Fax (336) 436-8645
Patient Last Name SAMPLE REPORT		Patient First Name 123638		Account Address <b>LabCorp Test Master Test Account</b> <b>3060 South Church Street</b> <b>Burlington, NC 27215</b>		
Age 56	Date of Birth 11/13/1959	Sex M	Fasting NOT SPECIFIED			
Control Number		NPI				
Date Collected 10/12/2016	Date Entered 10/12/2016	Date and Time Reported 10/12/2016 11:23 AM ET		Physician ID & Name		Page Number 2 of 2

## PARTICLE CONCENTRATION AND SIZE



\*\* The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment. Neither the LP-IR score nor the subclasses listed above have been cleared by the US Food and Drug Administration.

① LipoScience reference population comprises 4,588 men and women without known CVD or diabetes and not on lipid medication.

② Shalauraova I et al., Metab Syndr Relat Disord 2014; 12:422-9.

③ Mackey RH et al., Diab Care 2015; 38:628-36.